Author(s):
Ankita Dhavale, Pratibha Daroi, Bhushan Sonawane, Vijay Kumar M.
Email(s):
pratibhaadaroi@gmail.com
DOI:
10.52711/0974-360X.2024.00565 
Address:
Ankita Dhavale1*, Pratibha Daroi1, Bhushan Sonawane2, Vijay Kumar M.2
1Department of Quality Assurance, Gahlot Institute of Pharmacy, Plot No. 59, Sector-14, Koparkhairane, Navi Mumbai – 400709, Maharashtra, India.
2Analytical Research and Development, Central Drug Testing Laboratory, Zonal FDA Bhavan, GMSD Compound, Belasis Road, Mumbai Central, Mumbai – 400008, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 8,
Year - 2024
ABSTRACT:
A new, simple, accurate, fast, economic and precise high performance thin layer chromatography (HPTLC) method was developed and validated for the estimation of alectinib in a capsule dosage form. Separation of active ingredient from alectinib capsule was done on pre-coated HPTLC plate (silica gel 60 F254) and mobile phase consisting of Toluene: Methanol: Ethyl acetate: Glacial acetic acid in the ratio of 6:2:2:1v/v/v/v. Analysis of alectinib was carried out at the wavelength of 340nm. This system well-resolved bands for alectinib at a Rf value of 0.4. The current method has been statistically validated in accordance with the ICH Q2 (R1) guidelines. Linearity was found to be in the concentration range of 100-1500ng/band with the correlation coefficient of 0.999. Good accuracy and precision were obtained as revealed from %RSD value less than 2.
Cite this article:
Ankita Dhavale, Pratibha Daroi, Bhushan Sonawane, Vijay Kumar M.. Development and Validation of HPTLC Method for the Estimation of Alectinib in Capsule Dosage Form. Research Journal of Pharmacy and Technology. 2024; 17(8):3620-4. doi: 10.52711/0974-360X.2024.00565
Cite(Electronic):
Ankita Dhavale, Pratibha Daroi, Bhushan Sonawane, Vijay Kumar M.. Development and Validation of HPTLC Method for the Estimation of Alectinib in Capsule Dosage Form. Research Journal of Pharmacy and Technology. 2024; 17(8):3620-4. doi: 10.52711/0974-360X.2024.00565 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-8-13
7. REFERENCES:
1. Dziadziuszko R. Peters S. Ruf T. et al. Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. ESMO Open. 2022; 7(6): 100612. doi:10.1016/j.esmoop.2022.100612
2. Van Veelen A. van Geel R Schoufs R. et al. Development and validation of an HPLC–MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run. 2021; 35(12). doi:10.1002/bmc.5224
3. Huang XX. Li YX. et al. An UPLC–MS/MS method for the quantitation of alectinib in rat plasma. J 2017; 132: 227-231.
4. Bandla J. Ganapaty S. New Stability-Indicating Ultra Performance Liquid Chromatography Method Development And Validation Of Lenvatinib Mesylate In Bulk Drug And Pharmaceutical Dosage Forms. 2018; 11(9): 140-143.
5. Heinig K. Herzog D. Ferrari L. Fraier D. Miya K. Morcos PN. LC–MS/MS determination of alectinib and its major human metabolite M4 in human urine: prevention of nonspecific binding. Bioanalysis. 2017; 9(5): 459-468.
6. Eldin AB. Shalaby AA. El Maamly MY. Development and validation of a HPLC method for the determination of voriconazole and its degradation products in pharmaceutical formulation. Acta Pharm Sci. 2010; 52: 229-238.
7. Morcos PN. Yu L. Bogman K. et al. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica. 2017; 47(3): 217-229.
8. Jain V. Jain T. Saraf S. HPTLC method for routine quality control of Ayurvedic formulation Drakshadi gutika. Asian J Pharm Anal. 2013; 3(4): 111-114.
9. Arivukkarasu R. Rajasekaran A. Detection of flavonoids, phenolic acids and xanthones in commercial herbal formulations by HPTLC technique. Res J Pharmacogn Phytochem. 2015; 7(1): 13-27.
10. Ahmad W. Jawed R. Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Levamisole HCl in Bulk and Tablet Dosage Form. Published online 2022. doi: 10.52711/0975-4377.2022.00017
11. Sahoo MR. Anithakumari R. Palanichamy G. Guru B. Analytical Profiling of Saffron (Crocus sativus) using 1H-NMR and FTIR based Metabolomics approach and UV-Vis, HPTLC and TLC Chromatography Fingerprinting. Res J Pharmacogn Phytochem. 2023; 15(3): 191-197.
12. Agrawal MR. Aher AN. Pal SC. Isolation, Characterization of Phytoconstituents from petroleum ether extract of Momordica balsamina fruits and its quantitative analysis by HPTLC. Res J Pharmacogn Phytochem. 2020; 12(3): 156-161.
13. Chorawala H. Dedania ZR. Vijendraswamy SM. Development and Validation of UV Spectroscopic Method for Simultaneous Estimation of Doxofylline and Terbutaline Sulphate in Combined Dosage Form. Asian J Pharm Anal. 2015; 5(2): 74-78.
14. Krishna K. Sankar KG. Vardhan MS. Krishna SR. Tamizhmani T. Simultaneous estimation of gallic acid and rutin in Kaishore guggulu and Vatari guggulu by HPTLC. Res J Pharmacogn Phytochem. 2018; 10(3): 221-225.
15. Parmar RP. Kanaki NS. Development of Simultaneous HPTLC Method for estimation of Boswellic acid, Curcumin and Diosgenin in Polyherbal Transdermal Gel. Res J Pharmacogn Phytochem. 2018; 10(2): 163-167.
16. Çelebier M. Reçber T. Koçak E. Altinöz S. RP-HPLC method development and validation for estimation of rivaroxaban in pharmaceutical dosage forms. Brazilian J Pharm Sci. 2013; 49: 359-366.
17. Ghagare P. Patil A. Deshmane B. Kondawar M. Review on Pharmaceutical Validation. Res. J. Pharma. Dosage Forms and Tech. 2020; 12(1): 17-26. doi: 10.5958/0975-4377.2020.00004.X.
18. Samson I. Shiny G. B. Vinay K. A Rapid RP HPLC Method Development and Validation for the Analysis of Divalproex in Bulk and Pharmaceutical Dosage Forms. Asian J. Pharm. Ana. 6(1): January- March, 2016; 15-22. doi: 10.5958/2231-5675.2016.00003.X
19. Nikam P. Baokar S. Undare S. Patil R.N. Spectrophotometric Method Development and Validation of Prazosin. Research J. Science and Tech. 2016; 8(1): 1-4. doi: 10.5958/2349-2988.2016.00001.2.
20. Tian HX. Zhang XC. Yang JJ. et al. Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer. 2017; 114: 90-95. doi: 10.1016/j.lungcan.2017.11.001.
21. Shaw A.T. Gandhi L. Gadgeel S. Riely G.J. Cetnar, J. West H. Camidge D.R. Socinski M.A. Chiappori A. Mekhail T. and Chao B.H. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. The Lancet Oncology. 2016;17(2): 234-242. doi:10.4155/bio-2016-0284.
22. Soria, J.C. Ohe, Y. Vansteenkiste J.Reungwetwattana T. Chewaskulyong B. Lee K.H. DechaphunkulA. Imamura F. Nogami N. Kurata T. and Okamoto I. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. New England Journal of Medicine. 2018; 378(2): 113-125. doi:https://doi.org/10.1056/NEJMoa1713137.
23. Gainor F. Ou I. Logan J. Borges F. and Shaw T. The central nervous system as a sanctuary site in ALK-positive non–small-cell lung cancer. Journal of Thoracic Oncology.2013; 8(12): 1570-1573. doi: 10.1097/JTO.0000000000000029.
24. Zhou X. Shou J. Sheng J. Xu C. Ren S et al Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer. Cancer Science, 2019; 110(10): 3382-3390. doi: https://doi.org/10.1111/cas.14177.